Skip to main content
Erschienen in: Advances in Therapy 5/2020

10.04.2020 | Original Research

Comparable Effect of Two-Step Versus Extended Infusions on the Pharmacokinetics of Imipenem in Patients with Sepsis and Septic Shock

verfasst von: Yingzi Huang, Kang Xu, Ying Zhan, Xian Zha, Songqiao Liu, Jianfeng Xie, Lin Liu, Qing Li, Hua Shao, Yi Yang

Erschienen in: Advances in Therapy | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The present study aimed to compare the pharmacokinetic/pharmacodynamic (PK/PD) parameters of imipenem administered by two-step (50% delivered in a 30-min bolus, 50% for the following 90 min) or extended (administered continuously for 2 h) infusion.

Methods

Patients with sepsis and septic shock were prospectively enrolled and randomized into four groups. Subjects in the two-step or extended groups were given two doses of imipenem (0.5 g q6h and 1.0 g q8h). The plasma imipenem concentrations were measured at given time points after the fifth dose. The PK/PD target was defined as the achievement of a fractional time above the minimal inhibitory concentration (MIC) of > 40%.

Results

Thirty-five patients were eventually enrolled. No significant difference was observed in the percentage of patients achieving 40% T > MIC between the different infusion modes with the same dosage, although the two-step groups exhibited a significantly shorter Tmax compared with the extended groups (0.5 g q6h: 1.5 ± 0.8 vs. 2.0 ± 0.0 h; 1.0 g q8h: 1.0 ± 0.6 vs. 2.0 ± 0.0 h; both, p < 0.05). All four groups achieved 40% T > MIC when MIC was 0.5–4.0 μg/ml, but only regimens with a higher dose (1.0 g q8h) achieved target when MIC was 8 μg/ml.

Conclusion

The two-step and extended regimens of imipenem are comparable to the PK/PD target in the treatment of sepsis and septic shock. A higher dose (1.0 g q8h) should be considered for target achievement at an MIC of > 8 μg/ml.

Trial Registration

ClinicalTrials.gov identifier, NCT02616354.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Donnelly JP, Safford MM, Shapiro NI, Baddley JW, Wang HE. Application of the Third International Consensus Definitions for Sepsis (Sepsis-3) Classification: a retrospective population-based cohort study. Lancet Infect Dis. 2017;17:661–70.CrossRef Donnelly JP, Safford MM, Shapiro NI, Baddley JW, Wang HE. Application of the Third International Consensus Definitions for Sepsis (Sepsis-3) Classification: a retrospective population-based cohort study. Lancet Infect Dis. 2017;17:661–70.CrossRef
2.
Zurück zum Zitat Herran-Monge R, Muriel-Bombin A, Garcia-Garcia MM, et al. Epidemiology and changes in mortality of sepsis after the implementation of surviving sepsis campaign guidelines. J Intensive Care Med. 2017;34:740–50.CrossRef Herran-Monge R, Muriel-Bombin A, Garcia-Garcia MM, et al. Epidemiology and changes in mortality of sepsis after the implementation of surviving sepsis campaign guidelines. J Intensive Care Med. 2017;34:740–50.CrossRef
3.
Zurück zum Zitat Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43:304–77.CrossRef Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43:304–77.CrossRef
4.
Zurück zum Zitat Rello J, Valenzuela-Sanchez F, Ruiz-Rodriguez M, Moyano S. Sepsis: a review of advances in management. Adv Ther. 2017;34:2393–411.CrossRef Rello J, Valenzuela-Sanchez F, Ruiz-Rodriguez M, Moyano S. Sepsis: a review of advances in management. Adv Ther. 2017;34:2393–411.CrossRef
5.
Zurück zum Zitat van Hasselt JG, Rizk ML, Lala M, et al. Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid. Br J Clin Pharmacol. 2016;81:1113–23.CrossRef van Hasselt JG, Rizk ML, Lala M, et al. Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid. Br J Clin Pharmacol. 2016;81:1113–23.CrossRef
6.
Zurück zum Zitat Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis. 1995;22:89–96.CrossRef Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis. 1995;22:89–96.CrossRef
7.
Zurück zum Zitat Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis. 1988;158:831–47.CrossRef Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis. 1988;158:831–47.CrossRef
8.
Zurück zum Zitat Sinnollareddy MG, Roberts MS, Lipman J, Roberts JA. Beta-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review. Clin Exp Pharmacol Physiol. 2012;39:489–96.CrossRef Sinnollareddy MG, Roberts MS, Lipman J, Roberts JA. Beta-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review. Clin Exp Pharmacol Physiol. 2012;39:489–96.CrossRef
10.
Zurück zum Zitat Krueger WA, Bulitta J, Kinzig-Schippers M, et al. Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother. 2005;49:1881–9.CrossRef Krueger WA, Bulitta J, Kinzig-Schippers M, et al. Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother. 2005;49:1881–9.CrossRef
11.
Zurück zum Zitat Lorente L, Lorenzo L, Martin MM, Jimenez A, Mora ML. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother. 2006;40:219–23.CrossRef Lorente L, Lorenzo L, Martin MM, Jimenez A, Mora ML. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother. 2006;40:219–23.CrossRef
12.
Zurück zum Zitat Viaene E, Chanteux H, Servais H, Mingeot-Leclercq MP, Tulkens PM. Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother. 2002;46:2327–32.CrossRef Viaene E, Chanteux H, Servais H, Mingeot-Leclercq MP, Tulkens PM. Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother. 2002;46:2327–32.CrossRef
13.
Zurück zum Zitat Jaruratanasirikul S, Sriwiriyajan S, Punyo J. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother. 2005;49:1337–9.CrossRef Jaruratanasirikul S, Sriwiriyajan S, Punyo J. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother. 2005;49:1337–9.CrossRef
14.
Zurück zum Zitat Lee LS, Kinzig-Schippers M, Nafziger AN, et al. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation. Diagn Microbiol Infect Dis. 2010;68:251–8.CrossRef Lee LS, Kinzig-Schippers M, Nafziger AN, et al. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation. Diagn Microbiol Infect Dis. 2010;68:251–8.CrossRef
15.
Zurück zum Zitat Eguchi K, Kanazawa K, Shimizudani T, Kanemitsu K, Kaku M. Experimental verification of the efficacy of optimized two-step infusion therapy with meropenem using an in vitro pharmacodynamic model and Monte Carlo simulation. J Infect Chemother. 2010;16:1–9.CrossRef Eguchi K, Kanazawa K, Shimizudani T, Kanemitsu K, Kaku M. Experimental verification of the efficacy of optimized two-step infusion therapy with meropenem using an in vitro pharmacodynamic model and Monte Carlo simulation. J Infect Chemother. 2010;16:1–9.CrossRef
16.
Zurück zum Zitat Garcia-Capdevila L, Lopez-Calull C, Arroyo C, Moral MA, Mangues MA, Bonal J. Determination of imipenem in plasma by high-performance liquid chromatography for pharmacokinetic studies in patients. J Chromatogr B Biomed Sci Appl. 1997;692:127–32.CrossRef Garcia-Capdevila L, Lopez-Calull C, Arroyo C, Moral MA, Mangues MA, Bonal J. Determination of imipenem in plasma by high-performance liquid chromatography for pharmacokinetic studies in patients. J Chromatogr B Biomed Sci Appl. 1997;692:127–32.CrossRef
17.
Zurück zum Zitat Dailly E, Bouquie R, Deslandes G, Jolliet P, Le Floch R. A liquid chromatography assay for a quantification of doripenem, ertapenem, imipenem, meropenem concentrations in human plasma: application to a clinical pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879:1137–42.CrossRef Dailly E, Bouquie R, Deslandes G, Jolliet P, Le Floch R. A liquid chromatography assay for a quantification of doripenem, ertapenem, imipenem, meropenem concentrations in human plasma: application to a clinical pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879:1137–42.CrossRef
18.
Zurück zum Zitat Lewis SJ, Kays MB, Mueller BA. Use of Monte Carlo simulations to determine optimal carbapenem dosing in critically ill patients receiving prolonged intermittent renal replacement therapy. J Clin Pharmacol. 2016;56:1277–87.CrossRef Lewis SJ, Kays MB, Mueller BA. Use of Monte Carlo simulations to determine optimal carbapenem dosing in critically ill patients receiving prolonged intermittent renal replacement therapy. J Clin Pharmacol. 2016;56:1277–87.CrossRef
19.
Zurück zum Zitat Drusano GL, Plaisance KI, Forrest A, et al. Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients. Antimicrob Agents Chemother. 1987;31:1420–2.CrossRef Drusano GL, Plaisance KI, Forrest A, et al. Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients. Antimicrob Agents Chemother. 1987;31:1420–2.CrossRef
20.
Zurück zum Zitat Sakka SG, Glauner AK, Bulitta JB, et al. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother. 2007;51:3304–10.CrossRef Sakka SG, Glauner AK, Bulitta JB, et al. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother. 2007;51:3304–10.CrossRef
21.
Zurück zum Zitat De Paepe P, Belpaire FM, Buylaert WA. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet. 2002;41:1135–51.CrossRef De Paepe P, Belpaire FM, Buylaert WA. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet. 2002;41:1135–51.CrossRef
22.
Zurück zum Zitat Lips M, Siller M, Strojil J, Urbanek K, Balik M, Suchankova H. Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions. Int J Antimicrob Agents. 2014;44:358–62.CrossRef Lips M, Siller M, Strojil J, Urbanek K, Balik M, Suchankova H. Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions. Int J Antimicrob Agents. 2014;44:358–62.CrossRef
23.
Zurück zum Zitat Couffignal C, Pajot O, Laouenan C, et al. Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens. Br J Clin Pharmacol. 2014;78:1022–34.CrossRef Couffignal C, Pajot O, Laouenan C, et al. Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens. Br J Clin Pharmacol. 2014;78:1022–34.CrossRef
24.
Zurück zum Zitat De Waele JJ, Lipman J, Akova M, et al. Risk factors for target non-attainment during empirical treatment with beta-lactam antibiotics in critically ill patients. Intensive Care Med. 2014;40:1340–51.CrossRef De Waele JJ, Lipman J, Akova M, et al. Risk factors for target non-attainment during empirical treatment with beta-lactam antibiotics in critically ill patients. Intensive Care Med. 2014;40:1340–51.CrossRef
Metadaten
Titel
Comparable Effect of Two-Step Versus Extended Infusions on the Pharmacokinetics of Imipenem in Patients with Sepsis and Septic Shock
verfasst von
Yingzi Huang
Kang Xu
Ying Zhan
Xian Zha
Songqiao Liu
Jianfeng Xie
Lin Liu
Qing Li
Hua Shao
Yi Yang
Publikationsdatum
10.04.2020
Verlag
Springer Healthcare
Erschienen in
Advances in Therapy / Ausgabe 5/2020
Print ISSN: 0741-238X
Elektronische ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-020-01339-5

Weitere Artikel der Ausgabe 5/2020

Advances in Therapy 5/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.